Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some …
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
EffRx will be attending Europe’s largest life science partnering conference, BIO-Europe, which offers countless opportunities to engage with global life science partners. This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,000 companies for three days of high-level networking. To set up a meeting, please …
EffRx Pharmaceuticals SA is proud to announce that it will attend the upcoming medical meeting bisphosphonates2019 – Celebrating 50 years, taking place 15-17th of July 2019 in Sheffield, UK. The year 2019 marks 50 years since the first publication on the biological effects of the bisphosphonates. The meeting which focuses 100% on bisphosphonates will review …
FREIENBACH, Switzerland (BUSINESS WIRE) – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has entered into an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® (mannitol) for cystic fibrosis in Switzerland. Under …
BIO International Convention is back in Philadelphia, June 3-6, 2019 to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 67 countries.
EffRx would like to thank everyone who helped make the Binosto® booth a success at the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. With more than 4,000 delegates, the WCO-IOF-ESCEO Congress was an optimal platform for showcasing our lead product Binosto®.
FREIENBACH, Switzerland–(BUSINESS WIRE)– EffRx Pharmaceuticals SA is proud to announce that it will participate in the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, taking place April 4-7, 2019 in Paris. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue …
EffRx to Showcase Binosto® at the WCO-IOF-ESCEO 2019 in Paris Read More »
The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases. Rare …
Rare Disease Day is on February 28, 2019 – Help Raise Awareness Read More »
FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on niche therapeutics in Europe, today announced the recent expansion of the Executive Team with Lorraine Zakin, MD, as Director, Medical Affairs, Peter Lichtlen, MD, PhD as Chief Medical Advisor, Christiane Sievert as Director, Regulatory Affairs and Victor Papavasileiou as Vice President, Business Development. Lorenzo …
EffRx launches Binosto® – buffered soluble alendronate – in Malaysia and Singapore FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA today announced that physicians in Malaysia and Singapore treating patients with postmenopausal osteoporosis have a new therapeutic option: buffered soluble alendronate (Binosto®). This novel therapeutic option, which is already available in fifteen countries worldwide, provides gold-standard fracture risk …
EffRx Pharmaceuticals: Osteoporosis Patients in Southeast Asia Get Access to Binosto® Read More »
World Osteoporosis Day – WOD, marked on October 20th each year, is year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal disease. It aims to put bone health and fracture prevention on the global health agenda and reaches out to health-care professionals, the media, policy makers, …
World Osteoporosis Day – WOD on October 20th: Help Spread the Word Read More »
FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA is proud to announce that recent data from a standardized clinical database suggest an improved safety and tolerability profile of Binosto® (alendronate effervescent tablets) over conventional alendronate tablets in postmenopausal women with osteoporosis, translating into higher treatment persistence of patients. Binosto was also found to be as effective as traditional …
BIO International Convention is back in Boston, June 4-7, to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 74 countries.
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue …
FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to …
EffRx to Showcase Binosto® at WCO-IOF-ESCEO 2018 in Krakow, Poland Read More »
The European pharmaceutical market offers many opportunities for U.S. biopharmaceutical companies. An early engagement as well as a visceral understanding of the heterogeneity of the European market are key to succeed. Partnering with EffRx Pharmaceuticals, a commercial-stage pharmaceutical company offers various advantages. Because of its diversity and non-bureaucratic access to a talented workforce, EffRx an …
European Market-Entry Strategy for Biopharma Companies Read More »
The 23rd Annual BIO-Europe International Conference is the “must-attend” event and Europe’s largest life science partnering conference. And EffRx will be there. The conference brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more. To arrange for a meeting, please …
FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA is proud to inform that the latest safety data on Binosto® were presented as a poster on Sunday, 10th of September 2017 at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting in Denver, Colorado, USA attended by more than 3,000 scientists from 70 countries. Binosto®, the …
Binosto Data Presented at the ASBMR Congress in Denver Read More »
EffRx will participate in the parterning forum at the BIO International Convention (BIO). BIO attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. They bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology …
EffRx launches Binosto® – the first and only buffered solution for the treatment of osteoporosis – in two more markets. Freienbach, Switzerland, 8. June 2017 – EffRx Pharmaceuticals SA today announced that physicians in Germany and Russia treating patients with postmenopausal osteoporosis have a new therapy option: buffered soluble alendronate (Binosto®). This novel formulation, which …
Osteoporosis patients in Germany and Russia get access to Binosto® Read More »
Freienbach, Switzerland, June 1st, 2017 – EffRx Pharmaceuticals SA announced today the appointment of Mr. Paolo Agnoluzzi as Chief Financial Officer effective June 1st, 2017. Mr. Agnoluzzi joined EffRx in August 2016 as Interim Chief Financial Officer and led the re-organization of the Finance Department. Among other achievements he executed a number of debt and …
Paolo Agnoluzzi Appointed CFO of EffRx Pharmaceuticals Read More »
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy, from 23 to 26 March 2017. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue …
Binosto data to be presented at the WCO-IOF-ESCEO Congress in Florence Read More »
IOF-ECTS Position Paper provides recommendations for the screening of adherence to oral bisphosphonates; proposes assessment using PINP and CTX bone turnover markers (BTMs) at baseline and after three months. Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue …
Bone markers as screening strategy for patient adherence to osteoporosis medications Read More »
EffRx Pharmaceuticals will be attending the 35th Annual J.P. Morgan Heathcare Conference to take place from January 9-12, 2017 at the Westin St. Francis Hotel in San Francisco, California. To arrange for a meeting, please contact us at info@effrx.com
EffRx Pharmaceuticals will be attending the 22nd Annual International Partnering Conference in Cologne, Germany. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. To arrange for a meeting with us, please contact us via the BIO-Europe partnering platform or at info@effrx.com
Freienbach, Switzerland, October 11th, 2016 – EffRx Pharmaceuticals SA announced that the Company has made some changes and additions to its management team. Lorenzo Bosisio has been appointed as Chief Executive Officer effective July 1st, 2016. Prior to his promotion to CEO, Mr. Bosisio served as Chief Commercial Officer since 2013. During his tenure in …
Lorenzo Bosisio Appointed CEO of EffRx Pharmaceuticals Read More »
Freienbach, June 14th, 2016 — EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for orphan and specialty indications, today announced the appointment of Dr. Jonas Ekblom as Chairman and Dr. Alcide Barberis as Member of the Board of Directors. “I feel elated to join the Board of this …
EffRx Announces Changes in the Composition of the Board of Directors Read More »
Internis Pharma Binosto is now widely available across the UK, offering patients with osteoporosis the chance to access the first buffered formulation of alendronate designed to minimise gastrointestinal side effects commonly linked with traditional versions of the drug.
BioPortfolio, May 20, 2016 — The first buffered alendronate designed to minimise gastrointestinal side effects commonly associated with traditional alendronate treatment Huddersfield, 19 May, 2016, Internis Pharmaceuticals Ltd: Binosto, the first buffered alendronate (alendronate acid 70mg); is now available on prescription as an effervescent tablet. Binosto has been specifically designed to overcome the serious difficulties …
Binosto® now available for the effective treatment of postmenopausal osteoporosis Read More »
